Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in Finland
Real World Evidence Study on Metastatic Prostate Cancer Patient Characteristics, Treatment Patterns and Outcomes in the Pirkanmaa Hospital District in Finland
Sponsor: Pfizer
No open prediction endpoints
Endpoints are classified and published by ProgramSignal analysts.
Request endpoint coverageKey Facts
Primary Endpoints (CT.gov)
Body Mass Index (BMI)
Time frame: 3 months before index date (closest value); retrospective available data evaluated in this study for approximately 14 months
Prostate-Specific Antigen (PSA)
Time frame: 3 months before index date (closest value); retrospective available data evaluated in this study for approximately 14 months
Alkaline Phosphatase (P-AFOS)
Time frame: 3 months before index date (closest value); retrospective available data evaluated in this study for approximately 14 months
Length of Follow-up
Time frame: From index date to end of follow-up date [death or end of identification 31-Dec-2022, whichever occurred first], maximum up to approx.9 years; retrospective available data evaluated in this study for approximately 14 months
Eligibility Criteria
Inclusion Criteria: * Diagnosis of prostate cancer between 1/1/2007 - 12/31/2022 * Resident of Pirkanmaa at index date (diagnosis of mCSPC and/or mCRPC) * Detection of metastatic prostate cancer Exclusion Criteria: * Prevalent mCSPC and mCRPC patients (mCSPC or mCRPC diagnosis date before 1/1/2014 * Patient has another cancer diagnosis or the patient has received chemotherapy other than docetaxel or cabazitaxel within 2 years of mPC diagnosis.
✦ Analyst Commentary
Expert commentary on why this trial matters and what to watch for.
Request coverage →